CGM Adhesive Technology Landscape 2026 — PatSnap Eureka
Continuous Glucose Monitor Adhesive Technology Landscape 2026
From biocompatible hydrogels to pressure-sensitive acrylic systems, CGM adhesive innovation is accelerating. Discover which technologies are winning the race for reliable, comfortable, multi-day skin attachment — and who holds the key patents.
Four Adhesive Technology Families Defining CGM Wearability
Every CGM device that stays on skin for up to 14 days relies on one or more of these adhesive technology approaches — each with distinct patent activity, performance trade-offs, and regulatory considerations.
Pressure-Sensitive Adhesives (PSA)
Acrylic-based FDA-regulated PSAs form the dominant adhesive layer in most commercial CGM mounts. They provide immediate tack on skin contact without heat or solvent activation, and are engineered with specific peel and shear strength profiles to support 7–14 day wear. Formulation choices — including crosslinker density and tackifier selection — directly govern adhesion durability versus skin trauma on removal. Explore the full PSA patent landscape on PatSnap Eureka.
Dominant commercial approachHydrogel-Based Adhesive Systems
Hydrogel adhesives offer superior skin conformability and moisture management compared to conventional PSAs, making them attractive for patients with sensitive skin or high activity levels. Their water-swollen polymer networks maintain adhesion through perspiration while reducing maceration risk. Hydrogel formulations require careful balance of water content, crosslink density, and adhesive strength — and are increasingly protected by layered IP from both device OEMs and speciality material suppliers. The NIH has published extensive research on hydrogel biocompatibility relevant to this category.
Fastest-growing patent categoryMulti-Layer Patch Architectures
Multi-layer systems combine a breathable backing film (typically polyurethane), a primary adhesive layer, and sometimes a secondary release-liner-activated adhesive ring. The backing film's moisture vapour transmission rate (MVTR) — minimum 500 g/m²/day for clinical performance — prevents sweat accumulation that would degrade adhesion. Patent claims in this category frequently cover the specific layer stack, film thickness tolerances, and edge-seal geometries that prevent peel initiation at the patch perimeter. PatSnap Analytics can map the full multi-layer patent landscape for your R&D team.
Complex IP landscapeOverpatches & Secondary Adhesion Systems
Overpatches are secondary adhesive patches applied over the primary CGM mount to extend wear duration, reinforce adhesion during physical activity, or protect the sensor from water ingress. They represent a significant aftermarket and OEM-accessory segment, with specialised suppliers producing skin-tone-matched, hypoallergenic, and sport-specific variants. Overpatch design must accommodate the sensor transmitter profile while maintaining a low-profile, flexible form factor compatible with the primary device geometry.
Growing aftermarket segmentWhat CGM Adhesives Must Achieve to Reach the Market
CGM adhesive systems face a uniquely demanding performance envelope. The adhesive must maintain secure skin attachment for 7–14 days through activities including showering, swimming, and vigorous exercise — while remaining gentle enough to avoid medical adhesive-related skin injuries (MARSI) on removal. This dual requirement drives most of the innovation complexity in the category.
Water resistance is a non-negotiable specification. Most commercial CGM systems are rated swim-proof to 1–2.5 metres depth, requiring the adhesive and backing film combination to prevent water ingress at the sensor insertion site. The backing film's MVTR must exceed 500 g/m²/day to prevent sweat-driven delamination while maintaining the waterproof barrier function.
Biocompatibility assessment under ISO 10993 standards governs all adhesive component selection. Every material in the patch stack — including release liners, backing films, and adhesive layers — must demonstrate safe performance across the full intended wear duration. Regulatory submissions to the FDA and for CE marking require complete biocompatibility data packages. PatSnap Life Sciences intelligence helps R&D teams navigate these regulatory requirements efficiently.
Adhesive performance must also be chemically neutral with respect to sensor electrochemistry. Adhesive components that migrate into the sensor membrane or interstitial fluid sampling zone can cause glucose signal drift, requiring formulation chemists to work closely with sensor design teams during development.
CGM Adhesive Patent Filing Trends & Technology Distribution
Patent filing volumes in the CGM skin adhesive space have grown consistently since 2019, driven by expanded CGM adoption, new market entrants, and the shift to longer wear-duration devices.
CGM Adhesive Patent Filing Trend 2019–2024
Annual patent filings in the CGM skin adhesive and wearable sensor attachment space have grown 182% from 2019 to 2024, reflecting rapid commercial expansion and intensifying IP competition.
Patent Filing Share by Adhesive Technology Category
Pressure-sensitive adhesives hold the largest filing share at 38%, while hydrogel systems are the fastest-growing category, reflecting the industry's push toward skin-friendly, high-comfort formulations.
Where CGM Adhesive R&D Is Moving in 2026
Beyond the four core technology categories, several cross-cutting innovation themes are reshaping how CGM adhesive systems are designed, tested, and commercialised.
Skin-Microbiome-Aware Formulations
Next-generation CGM adhesives are being developed with antimicrobial additives and pH-buffering agents that maintain skin microbiome balance during extended wear. Patent claims in this space cite specific antimicrobial agents at sub-irritant concentrations, designed to prevent bacterial growth at the adhesive-skin interface without disrupting the skin barrier function.
Skin-Tone-Matched & Aesthetic Overpatches
The overpatch segment is diversifying rapidly beyond functional performance into aesthetic differentiation. Manufacturers are filing patents covering pigmented adhesive films matched to Fitzpatrick skin tone classifications, UV-stable colorant systems, and patterned backing films. This reflects growing patient demand for CGM devices that are less visually conspicuous in daily life.
Sustainable & Bio-Based Adhesive Components
Regulatory pressure and corporate sustainability commitments are driving R&D into bio-based PSA feedstocks, including rosin-derived tackifiers and plant-based acrylate monomers. Patent activity in bio-based medical adhesives is growing, with applicants claiming specific bio-content percentages and equivalent adhesive performance to petroleum-derived benchmarks. PatSnap Chemicals intelligence tracks this emerging material category.
Conductive & Sensor-Integrated Adhesive Layers
An emerging frontier involves adhesive layers that serve dual functions — providing skin attachment and acting as a conductive interface for biosensor signal transmission. These systems use conductive polymers or nano-filler-loaded hydrogels to create electrically active adhesive layers, potentially simplifying CGM device architecture and reducing the number of discrete components requiring regulatory clearance.
CGM Adhesive Compliance Framework at a Glance
Every CGM adhesive system must satisfy a layered set of regulatory, performance, and material requirements before reaching patients. This framework governs both OEM device adhesives and aftermarket overpatch products.
| Requirement Area | Standard / Specification | Key Parameter | Applicability |
|---|---|---|---|
| Biocompatibility | ISO 10993 series | Cytotoxicity, sensitisation, irritation, systemic toxicity testing across full wear duration | All adhesive components including backing films and release liners |
| Wear Duration | Device labelling claim | 7–14 days continuous skin attachment through normal activities | Primary device adhesive and any OEM overpatch |
| Water Resistance | IP68 / device specification | Swim-proof to 1–2.5 metres depth; no water ingress at sensor site | Backing film + adhesive edge seal combination |
| Moisture Vapour Transmission | ASTM E96 / ISO 2528 | Minimum 500 g/m²/day MVTR to prevent sweat-driven delamination | Backing film selection and multi-layer stack design |
| Skin Compatibility | MARSI prevention guidelines | Atraumatic removal after 14-day wear; no epidermal stripping | Adhesive peel strength and tack formulation parameters |
| Sensor Neutrality | Device-specific validation | No adhesive component migration into sensor membrane or ISF sampling zone | All adhesive materials in proximity to sensor insertion site |
Map your CGM adhesive IP strategy against the competitive landscape
PatSnap Eureka gives your R&D and IP teams instant access to 2B+ data points across patents, literature, and regulatory filings.
CGM Adhesive Technology — key questions answered
CGM devices primarily use pressure-sensitive adhesives (PSAs), hydrogel-based adhesives, and acrylic-based formulations. These must balance strong skin adhesion for 7–14 day wear durations with biocompatibility, moisture management, and atraumatic removal. Overpatches and secondary adhesive layers are also commonly applied to extend wear time or reinforce the primary adhesive bond.
CGM sensors must remain securely attached to the skin for 7–14 days through activities including showering, swimming, and exercise. Adhesive failure leads to inaccurate glucose readings, device loss, and patient safety risks. The adhesive must also be gentle enough to avoid skin irritation, allergic reactions, or medical adhesive-related skin injuries (MARSI) over extended wear periods.
Key challenges include maintaining adhesion through sweat, water exposure, and body movement over multi-day wear; preventing skin irritation and allergic reactions from adhesive components; enabling clean, pain-free removal without skin stripping; managing moisture vapour transmission to prevent maceration; and ensuring the adhesive does not interfere with sensor electrochemistry or glucose signal transmission through the patch layers.
Leading CGM manufacturers differentiate through proprietary adhesive formulations, multi-layer patch architectures, and specialised backing materials. Some use breathable polyurethane films with acrylic PSA layers, while others employ hydrogel interfaces to improve skin contact and comfort. Overpatch accessories — secondary adhesive rings or sheets applied over the primary sensor mount — are a growing category, with both OEM and third-party suppliers competing in this space.
Overpatches are secondary adhesive patches applied on top of the primary CGM mount to extend wear duration, reinforce adhesion during physical activity, or protect the sensor from water ingress. They represent a significant aftermarket segment, with specialised suppliers producing skin-tone-matched, hypoallergenic, and sport-specific variants. Overpatch design must accommodate the sensor transmitter profile while maintaining a low-profile, flexible form factor.
CGM adhesive biocompatibility is assessed under ISO 10993 standards, which cover cytotoxicity, sensitisation, irritation, and systemic toxicity testing. Adhesives must demonstrate safe performance across the intended wear duration — typically 7–14 days — on intact skin. Regulatory submissions to the FDA and CE marking authorities require biocompatibility data packages covering all adhesive components including any release liners, backing films, and adhesive layers.
Still have questions about CGM adhesive patents or technology strategy? Let PatSnap Eureka answer them instantly.
Ask PatSnap EurekaAccelerate Your CGM Adhesive R&D with AI Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to navigate complex IP landscapes, identify white spaces, and bring better wearable medical devices to market faster.
References
- U.S. Food and Drug Administration (FDA) — Regulatory guidance on medical device adhesives, biocompatibility, and 510(k) clearance pathways for skin-worn glucose monitoring devices.
- International Organisation for Standardisation (ISO) — ISO 10993 series: Biological evaluation of medical devices — standards governing biocompatibility testing for skin-contact adhesive materials.
- National Institutes of Health (NIH) — Published research on hydrogel biocompatibility, skin adhesion mechanisms, and wearable biosensor integration relevant to CGM adhesive development.
- PatSnap Analytics — AI-powered patent landscape analysis platform used for CGM adhesive technology category mapping and filing trend data in this report.
- PatSnap Life Sciences Intelligence — Specialised R&D and IP intelligence for pharmaceutical, biotech, and medical device innovation including wearable glucose monitoring.
- PatSnap Chemicals Intelligence — Materials science and formulation patent intelligence covering bio-based adhesive feedstocks and advanced polymer systems for medical applications.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Patent filing volume figures are derived from PatSnap Eureka database analysis of CGM adhesive and wearable sensor attachment technology patent families filed 2019–2024.
PatSnap Eureka searches patents and research to answer instantly.